AVEO Pharmaceuticals, which is developing a renal cell carcinoma drug similar to blockbuster Avastin, will see its quiet period end on Tuesday, April 20th. On March 11th, the company raised $81 million by offering 9 million shares at $9, below the range of $13-$15. J.P. Morgan and Morgan Stanley acted as lead managers on the deal.
